OM:HNSA

Stock Analysis Report

Executive Summary

Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has Hansa Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.5%

HNSA

1.8%

SE Biotechs

1.9%

SE Market


1 Year Return

-56.8%

HNSA

-18.0%

SE Biotechs

9.6%

SE Market

Return vs Industry: HNSA underperformed the Swedish Biotechs industry which returned -18% over the past year.

Return vs Market: HNSA underperformed the Swedish Market which returned 9.6% over the past year.


Shareholder returns

HNSAIndustryMarket
7 Day-0.5%1.8%1.9%
30 Day-12.1%-1.9%-0.3%
90 Day-29.9%-11.7%0.7%
1 Year-56.8%-56.8%-17.5%-18.0%14.3%9.6%
3 Year74.7%74.7%29.5%19.2%31.5%11.9%
5 Year477.8%448.7%66.9%68.0%66.2%30.8%

Price Volatility Vs. Market

How volatile is Hansa Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Hansa Biopharma undervalued compared to its fair value and its price relative to the market?

6.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate HNSA's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate HNSA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HNSA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: HNSA is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate HNSA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HNSA is overvalued based on its PB Ratio (6.8x) compared to the SE Biotechs industry average (3.8x).


Next Steps

Future Growth

How is Hansa Biopharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

30.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HNSA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HNSA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HNSA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HNSA's revenue (64.3% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: HNSA's revenue (64.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if HNSA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Hansa Biopharma performed over the past 5 years?

-42.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: HNSA is unprofitable, and losses have increased over the past 5 years at a rate of -42.3% per year.

Accelerating Growth: Unable to compare HNSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HNSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.4%).


Return on Equity

High ROE: HNSA has a negative Return on Equity (-39.39%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: HNSA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: HNSA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Hansa Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: HNSA's short term assets (SEK767.5M) exceeds its short term liabilities (SEK49.7M)

Long Term Liabilities: HNSA's short term assets (767.5M) exceeds its long term liabilities (12.7M)


Debt to Equity History and Analysis

Debt Level: HNSA's debt to equity ratio (0.1%) is considered satisfactory

Reducing Debt: HNSA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: HNSA has a low level of unsold assets or inventory.

Debt Coverage by Assets: HNSA's debt is covered by short term assets (assets are 1035.784070x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HNSA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HNSA has sufficient cash runway for 1.145498 years if free cash flow continues to reduce at historical rates of -39.7% each year.


Next Steps

Dividend

What is Hansa Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate HNSA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HNSA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if HNSA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HNSA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HNSA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Hansa Biopharma's salary, the management and board of directors tenure and is there insider trading?

0.4yrs

Average management tenure


CEO

Søren Tulstrup (54yo)

1.6yrs

Tenure

0

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Medical AB (publ) since March 20, 2018. Mr. Tulstrup served as the Chief Executive Officer of Vifor Pharma Ltd. since Augus ...


Management Age and Tenure

0.4yrs

Average Tenure

52yo

Average Age

Experienced Management: HNSA's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.


Board Age and Tenure

1.4yrs

Average Tenure

64.5yo

Average Age

Experienced Board: HNSA's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buykr313,12004 Jun 19
Max Sakajja
EntityIndividual
Shares1,900
Max Pricekr164.80
Buykr447,94724 May 19
Andreas Eggert
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,500
Max Pricekr179.18
Buykr77,02823 May 19
Anne Lanner
EntityIndividual
Role
Head of Human Resources
Vice President of Global Human Resources
Shares360
Max Pricekr221.73
Buykr1,744,20022 May 19
Ulf Wiinberg
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max Pricekr174.42
Buykr925,00005 May 19
Søren Tulstrup
EntityIndividual
Role
Chief Executive Officer
President & CEO
Shares5,000
Max Pricekr185.00
Sellkr3,600,00003 May 19
Emanuel Björne
EntityIndividual
Shares20,000
Max Pricekr180.00

Ownership Breakdown


Management Team

  • Søren Tulstrup (54yo)

    President & CEO

    • Tenure: 1.6yrs
  • Christian Kjellman (52yo)

    Senior VP of Research & Development and Chief Scientific Officer

    • Tenure: 0.3yrs
  • Henk J. van Troostwijk (54yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 0.3yrs
  • Donato Spota (48yo)

    CFO & Senior VP

    • Tenure: 0.4yrs
  • Eva-Maria Joed (50yo)

    Vice President of Finance & Administration

    • Tenure: 0.4yrs
  • Anne Lanner

    Vice President of Global Human Resources

    • Tenure: 0.8yrs
  • Klaus Sindahl

    Head of Investor Relations

    • Tenure: 0yrs

Board Members

  • Birgit Norinder (71yo)

    Director

    • Tenure: 7.8yrs
    • Compensation: kr467.00k
  • Ulf Wiinberg (61yo)

    Chairman of the Board

    • Tenure: 1.6yrs
    • Compensation: kr2.56m
  • Anders Pedersen (68yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: kr210.00k
  • Eva Nilsagård (55yo)

    Director

    • Tenure: 0.4yrs
  • Andreas Eggert

    Director

    • Tenure: 1.4yrs
    • Compensation: kr204.00k
  • Gunnar Tufveson

    Chairman of European Medical Advisory Board in Transplantation

    • Tenure: 0yrs
  • Kathryn Wood

    Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation

    • Tenure: 0yrs
  • Christophe Legendre

    Member of European Medical Advisory Board in Transplantation

    • Tenure: 0yrs
  • Stanley Jordan

    Chairman of US Medical Advisory Board in Transplantation

    • Tenure: 0yrs
  • Robert Montgomery

    Member of US Medical Advisory Board in Transplantation

    • Tenure: 0yrs

Company Information

Hansa Biopharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hansa Biopharma AB (publ)
  • Ticker: HNSA
  • Exchange: OM
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr5.139b
  • Shares outstanding: 40.03m
  • Website: https://www.hansabiopharma.com

Number of Employees


Location

  • Hansa Biopharma AB (publ)
  • Scheelevägen 22
  • Lund
  • Skåne County
  • 222 63
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HNSAOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKOct 2007
HNSB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDOct 2007
0RC7LSE (London Stock Exchange)YesClass B SharesGBSEKOct 2007
24HDB (Deutsche Boerse AG)YesClass B SharesDEEUROct 2007

Biography

Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. The company’s lead drug candidate is Immunogl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 20:56
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.